glp 1 mash approval CDSCO Clears Wegovy for — India's First GLP-1 for Liver Disease, India's drug regulator CDSCO approved Novo Nordisk's Wegovy (semaglutide 2.4mg) on 17 July 2026 for MASH, based on Exploring the Potential of GLP-1

doi: 10.3892/etm.2021.10543

Effects of dipeptidyl peptidase-4 (DPP-4) inhibition on angiogenesis and hypoxic injury in type 2 diabetes

The studies have not yet been published in a peer-reviewed scientific journal, but a news release detailed some of these findings

Potentially, leptin therapy could sustain weight loss by overriding the tendency toward energy conservation

For those seeking additional compounds, injectable Semaglutide is $189 monthly month-to-month, or from $149/mo on the 6-month plan and injectable Tirzepatide is $289/mo month-to-month, or from $249/mo on the 6-month plan

Weight Loss: One of the most compelling benefits of GLP-1 therapy is its ability to promote weight loss